Gastric cancer is the fourth most common cancer worldwide, and the second most frequent cause of mortality ([@bib2]; [@bib10]). In Japan, although the incidence of gastric cancer has decreased, gastric cancer remains the most frequent cause of morbidity among patients with malignant tumours ([@bib7]). Although recent years have seen improvements in surgical techniques and adjuvant chemotherapy, the long-term survival of patients with advanced-stage gastric cancer remains unsatisfactory ([@bib25]).

There is increasing evidence that, in addition to tumour stage and the proliferative activity of tumour cells, the systemic inflammatory response is associated with malignancy ([@bib24]; [@bib18]; [@bib22]). C-reactive protein (CRP), an acute-phase response protein, has been proven to be an independent prognostic factor for survival in many malignancies, including gastric cancer ([@bib9]; [@bib23]). In addition, hypoalbuminemia, a typical index of malnutrition, has been reported to be associated with poor survival in advanced cancer ([@bib4]; [@bib15]). Recently, the Glasgow prognostic score (GPS), based on serum CRP and albumin levels, was developed to aid in the assessment of cancer prognosis ([@bib8]; [@bib22]). An elevated GPS has been shown to be associated with worse prognosis for a number of different tumours ([@bib19]). Thus, the GPS may be a prognostic marker in cancer, independent of stage and biochemical tumour markers ([@bib19]; [@bib24]).

The GPS has also been shown to be a prognostic factor in advanced gastrointestinal cancers, including oesophageal and colorectal cancer ([@bib12]; [@bib8]). However, only few studies have used the GPS for postoperative prognostication of patients with gastric cancer. Thus, in the present study, we collected data retrospectively from 1710 patients with operable gastric cancer and investigated the significance of the preoperative GPS for postoperative survival in these patients.

Materials and Methods
=====================

The gastric cancer database from the Department of Gastroenterological Surgery at The Cancer Institute Hospital, Tokyo, Japan, was reviewed retrospectively. Patients with gastric adenocarcinoma who had undergone curative (R0 resection) or palliative gastrectomy between January 2000 and December 2007 and for whom preoperative laboratory data for CRP and albumin were available were enrolled into the study. Palliative surgery is defined as the presence of any gross or microscopic residual tumours remaining postoperatively regardless of whether the surgical attempt was originally palliative or curative. Patients who died within 30 days after surgery, or those who died of non-cancer-related causes were excluded from the study. Patients who had other malignancies or who had inflammatory diseases that might have increased CRP levels were also excluded from the study. To remove any influence of neoadjuvant chemo/radiotherapy on survival or GPS, patients who received neoadjuvant chemotherapy or radiotherapy were also excluded. Using these criteria, 1710 patients with gastric cancer were enrolled in the present study. Patients were followed according to the established protocol in our hospital, including medical history, physical examination and laboratory studies 1 and 3 months after operation, and then every 6 months.

Pathological tumour stage (pTNM) was determined using the seventh edition of the AJCC cancer staging of stomach ([@bib27]). Blood samples were collected for routine laboratory measurements of CRP, albumin, complete blood count and tumour markers such as carcinoembryonic antigen (CEA) (cutoff value, 5 ng ml^−1^) and CA19-9 (cutoff value, 37 ng ml^−1^). The modified GPS (mGPS) was calculated as described previously ([@bib16]). Briefly, patients with elevated CRP (\>10 mg l^−1^) were assigned an mGPS of 1 or 2 depending on the absence or presence of hypoalbuminaemia (\<35 g l^−1^), whereas patients showing no elevated level of CRP (⩽10 mg l^−1^) are allocated an mGPS of 0, even if hypoalbuminaemia is present.

Statistical analysis
--------------------

Data are presented as mean and 95% confidence intervals (CI). Differences between groups were analysed using the Kaplan--Meier survival analysis or *χ*^2^ test. Survival analysis was performed using Cox proportional hazards model in a forward stepwise manner. Kaplan--Meier analysis and log-rank test were used to compare mortality for each mGPS. Deaths before 31 July 2010 were included in this analysis. *P*\<0.05 was considered significant. All statistical analyses were performed using SPSS version 13.0 (SPSS, Chicago, IL, USA).

Results
=======

During 2000--07, 2601 patients underwent gastric cancer surgery. Of these, 845 were excluded from analysis because data on their CRP and albumin levels were not available, and 46 were excluded because of neoadjuvant chemotherapy, postoperative death or non-cancer death. Of the 1710 included patients with gastric cancer (1157 men; 553 women), 240 (14.0%) had elevated CRP levels (\>10 mg l^−1^) and/or hypoalbuminemia (\<35 g l^−1^). Of these, 78 (4.6%) were given an mGPS of 1 and 67 (3.9%) were given an mGPS of 2. The median follow-up time was 43.0 (1--123) months. None of the patients was lost to follow-up.

The classified background demographics and their association with overall survival are given in [Table 1](#tbl1){ref-type="table"}. There was no significant difference in overall survival in terms of sex (male/female), white cell count (\<11/⩾11 × 10^9^ l^−1^) and lymphocytes (\<3/⩾3 × 10^9^ l^−1^). Conversely, significant differences in overall survival were found in relation to age (\<65/⩾65 years), body mass index (BMI; \<18.5/18.5--25/\>25 kg m^−2^), tumour location (upper/middle/lower third), neutrophils (\<7.5/⩾7.5 × 10^9^ l^−1^), CEA (⩽5/\>5 ng ml^−1^), CA19-9 (⩽37/\>37 ng ml^−1^), CRP (⩽10/\>10 mg l^−1^), albumin (\<35/⩾35 g l^−1^), tumour stage (I/II/III/IV) and mGPS (0/1/2).

The relationship between clinicolaboratory characteristics and mGPS is given in [Table 2](#tbl2){ref-type="table"}. Sex, age, BMI, white cell count, neutrophils, CEA, CA19-9 and tumour stage showed significant relationship with the mGPS. Conversely, mGPS was not affected by tumour location and lymphocytes.

Univariate analysis of postoperative mortality is indicated in [Table 3](#tbl3){ref-type="table"}. Seven factors were significantly associated with overall survival including age, BMI, neutrophils, CEA, CA19-9, tumour stage and mGPS. On multivariate analysis, factors with *P*\<0.1 in univariate analysis were included. Multivariate analysis revealed a significant association between postoperative mortality and age (odds ratio (OR), 1.319; 95% CI, 1.068--1.629; *P*=0.010), tumour stage (OR, 2.909; 95% CI, 2.616--3.234; *P*\<0.001) and the mGPS (OR, 1.845; 95% CI, 1.184--2.875; *P*=0.007) ([Table 3](#tbl3){ref-type="table"}).

The mean survival of patients with an mGPS of 0, 1 and 2 was 95.8, 62.2 and 35.9 months, respectively ([Table 1](#tbl1){ref-type="table"}). Kaplan--Meier analysis and log-rank test demonstrated significant differences among patients with mGPS of 0, 1 and 2 (*P*\<0.001), with the mortality rate higher for patients with a higher mGPS ([Figure 1](#fig1){ref-type="fig"}).

To clarify whether the mGPS has different prognostic value depending on tumour stage, patients were divided into two groups, namely those with relatively early-stage tumours (stage I; *n*=997) and those with advanced-stage tumours (stage II, III and IV; *n*=713). Significant differences in survival were found for patients with mGPS of 0, 1 and 2 in both groups (both *P*\<0.001) ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

Discussion
==========

The present retrospective study analysed individual clinical data for 1710 patients who underwent surgery for a pure cohort of gastric cancer in a high-volume center in Japan. The results demonstrate the prognostic value of the mGPS for gastric cancer. Although the GPS has been reported to have prognostic significance in a variety of cancers, its value in gastric cancer has not been fully investigated ([@bib5]; [@bib3]; [@bib20]). Furthermore, the GPS is usually considered to be correlated with postoperative survival only in very advanced cancer ([@bib8]; [@bib24]; [@bib26]). The present study included patients with gastric cancer who underwent gastrectomy; and the prognostic value of the mGPS in not only very advanced but also relatively early gastric cancer was evaluated. Currently, pathological TNM is considered the gold standard for predicting postoperative outcome, but it can only be properly evaluated postoperatively. On the other hand, preoperative TNM is not always accurate, and this causes the difficulty and bias for predicting survival preoperatively. The results of the present study indicate that the mGPS can predict postoperative survival for patients with gastric cancer. More importantly, the mGPS can be achieved easily before operation, and it seems not inferior to conventional tumour markers like CEA and CA19-9.

Numerous studies have reported that elevated CRP levels are indicative of a poor outcome in a variety of cancers ([@bib14]; [@bib9]; [@bib23]). For example, elevated CRP levels have been reported to be independent prognostic factors associated with tumour size, cancer stage, cancer cachexia and poor prognosis in many studies ([@bib21]; [@bib14]). [@bib11] reported a correlation between CRP levels and depth of invasion, lymph node metastasis and TNM stage in operable gastric cancer. Crumley *et al* (2010) reported that elevated CRP levels were a significant predictor of survival in gastric cancer. In the present study, the mean survival time of patients with elevated CRP levels (\>10 mg l^−1^) was significantly lower than that of patients with normal CRP levels (⩽10 mg l^−1^), which emphasises the correlation between CRP levels and prognosis.

Hypoalbuminemia is often observed in advanced cancer patients, and is usually regarded as a good index for malnutrition and cachexia. In gastric cancer, hypoalbuminemia is reported to be associated with poorer survival ([@bib17]; [@bib4]), which was also observed in the present study. Previous studies have indicated that hypoalbuminemia is likely to develop secondary to increases in serum CRP levels ([@bib1]). Furthermore, study of Crumley *et al* (2010) demonstrated that the relation of low albumin concentrations and poorer survival in patients with gastric cancer was dependent on the elevated CRP level. In the present study, hypoalbuminemia was significantly correlated with serum elevation of CRP (data not shown). So systemic inflammatory response, as evidenced by elevated CRP level, might have a key role in the progression of malnutrition and even cachexia in gastric cancer ([@bib6]; [@bib4]).

The GPS, which is based on both serum elevation of CRP and hypoalbuminemia, may enable a better appreciation of the effects of the tumour on both ongoing systemic inflammation and malnutrition. The GPS has been introduced to predict the prognosis of patients with very advanced neoplasms ([@bib8]; [@bib26]). Recently, Nozoe *et al* (2011) studied the significance of the GPS in 232 patients with operable gastric cancer and demonstrated the prognostic value of the GPS in these patients. The present study revealed that a higher mGPS was associated with poorer survival in patients with advanced gastric cancer (stage II, III and IV), which is in accordance with the results of previous studies evaluating the prognostic value of the mGPS in gastric and other cancers. In the present study, 268 patients were diagnosed as pathological stage IV gastric cancer according to seventh UICC TNM staging system of gastric cancer. These patients received gastrectomy either because they were not classified as stage IV gastric cancer preoperatively or they needed to receive palliative gastrectomy because of complications related to gastric cancer. On the other hand, interestingly, the present study also showed the significant survival differences depending on the mGPS in patients with relatively early-stage gastric cancer (stage I). In the 997 patients with stage I gastric cancer, the 5-year survival rates for patients with an mGPS of 0 (*n*=961), 1 (*n*=30) and 2 (*n*=6) were 93.0%, 82.8% and 66.7%, respectively (data not shown). Thus, the mGPS might also have prognostic value for survival in patients with relatively early-stage gastric cancer. However, the rate of mGPS 2 in patients with stage I gastric cancer was so low that it is too early to give a definite conclusion. Accumulation of more cases with mGPS 2 in stage I gastric cancer and survey of cancer-specific survival are warranted.

The results of the present study indicate that the mGPS may be a novel and simple biomarker in patients with gastric cancer. The findings of the present study may translate to potential improvements in the therapy of gastric cancer. For example, an mGPS of 2 was associated with very poor survival in the present study, so, for patients with both very advanced gastric cancer and an mGPS of 2, neoadjuvant chemotherapy may be beneficial. Similarly, these patients may require more aggressive adjuvant chemotherapy, such as S-1 plus cisplatin ([@bib13]). On the other hand, as patients with a higher mGPS had inflammatory response and/or malnutrition, anti-inflammatory therapy or nutritional support may have a beneficial effect on prognosis. It remains to be established whether patients with a higher mGPS need more active therapy.

In summary, the preoperative mGPS is a simple and useful prognostic factor for postoperative survival in patients with gastric cancer. The mGPS may be used together with traditional risk factors to individualise treatment strategies and the follow-up of patients with gastric cancer.
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###### Clinical and laboratory characteristics associated with overall survival

                                              **No. of patients**   **Overall survival (months), mean (95% CI)**   ***P*****-value**[a](#t1-fn2){ref-type="fn"}
  ------------------------------------------- --------------------- ---------------------------------------------- ----------------------------------------------
  *Sex*                                                                                                            
   Male                                       1157                  90.0 (87.0--93.0)                              0.185
   Female                                     553                   96.2 (91.9--100.5)                              
                                                                                                                    
  *Age (years)*                                                                                                    
   \<65                                       885                   98.1 (94.7--101.4)                             \<0.001
   ⩾65                                        813                   85.9 (82.1--89.8)                               
                                                                                                                    
  *Body mass index (kg m*^−2^)                                                                                     
   \<18.5                                     261                   61.4 (55.8--67.0)                              \<0.001
   18.5--25                                   1138                  96.1 (93.0--99.2)                               
   ⩾25                                        233                   96.1 (91.4--100.9)                              
                                                                                                                    
  *Tumour location*                                                                                                
   Upper third                                460                   79.2 (74.6--83.8)                              \<0.001
   Middle third                               772                   100.5 (96.9--104.2)                             
   Lower third                                470                   88.2 (83.1--93.3)                               
                                                                                                                    
  *White cell count ( × 10*^*9 *^*l*^−*1*^)                                                                        
   \<11                                       1682                  93.3 (90.7--96.0)                              0.156
   ⩾11                                        27                    60.4 (48.7--72.2)                               
                                                                                                                    
  *Neutrophils ( × 10*^*9 *^*l*^−*1*^)                                                                             
   \<7.5                                      1605                  94.0 (91.4--96.7)                              \<0.001
   ⩾7.5                                       50                    59.2 (46.1--72.3)                               
                                                                                                                    
  *Lymphocytes ( × 10*^*9 *^*l*^−*1*^)                                                                             
   \<3                                        1592                  92.9 (90.2--95.6)                              0.208
   ⩾3                                         63                    95.0 (85.4--104.6)                              
  *CEA (ng ml^−1^)*                                                                                                 
   ⩽5                                         1433                  95.4 (92.7--98.1)                              \<0.001
   \>5                                        233                   55.9 (49.9--61.8)                               
                                                                                                                    
  *CA19-9 (ng ml*^−*1*^)                                                                                           
   ⩽37                                        1406                  94.1 (91.4--96.8)                              \<0.001
   \>37                                       151                   48.5 (40.4--56.5)                               
                                                                                                                    
  *CRP (mg l*^−*1*^)                                                                                               
   ⩽10                                        1565                  95.8 (93.2--98.5)                              \<0.001
   \>10                                       145                   51.4 (44.5--58.2)                               
                                                                                                                    
  *Albumin (g l*^−*1*^)                                                                                            
   \<35                                       162                   38.8 (33.0--44.5)                              \<0.001
   ⩾35                                        1548                  97.8 (95.2--100.4)                              
                                                                                                                    
  *Tumour stage (pTNM)*                                                                                            
   I                                          997                   113.5 (111.0--116.0)                           \<0.001
   II                                         200                   82.6 (77.2--87.9)                               
   III                                        245                   68.1 (62.0--74.1)                               
   IV                                         268                   28.7 (23.9--33.5)                               
                                                                                                                    
  *mGPS*                                                                                                           
   0                                          1565                  95.8 (93.2--98.5)                              \<0.001
   1                                          78                    62.2 (53.4--71.1)                               
   2                                          67                    35.9 (27.0--44.8)                               

Abbreviations: CEA=carcinoembryonic antigen; CRP=C-reactive protein; mGPS=modified Glasgow prognostic score; pTNM=pathological tumour-node-metastasis staging.

Kaplan--Meier survival analysis.

###### Relationships between clinicolaboratory characteristics and mGPS

                                              **mGPS 0 n (%)**   **mGPS 1 n (%)**   **mGPS 2 n (%)**   ***P-*****value**[a](#t2-fn2){ref-type="fn"}
  ------------------------------------------- ------------------ ------------------ ------------------ ----------------------------------------------
  *Sex*                                                                                                
   Male                                       1045 (90.3)        60 (5.2)           52 (4.5)           0.036
   Female                                     520 (94.0)         18 (3.3)           15 (2.7)            
                                                                                                        
  *Age (years)*                                                                                        
   \<65                                       831 (93.9)         29 (3.3)           25 (2.8)           0.001
   ⩾65                                        723 (88.9)         48 (5.9)           42 (5.2)            
                                                                                                        
  *Body mass index (kg m*^−2^)                                                                         
   \<18.5                                     212 (81.2)         17 (6.5)           32 (12.3)          \<0.001
   18.5--25                                   1059 (93.1)        47 (4.1)           32 (2.8)            
   ⩾25                                        221 (94.8)         11 (4.7)           1 (0.4)             
                                                                                                        
  *Tumour location*                                                                                    
   Upper third                                414 (90.0)         22 (4.8)           24 (5.2)           0.069
   Middle third                               722 (93.5)         29 (3.8)           21 (2.7)            
   Lower third                                421 (89.6)         27 (5.7)           22 (4.7)            
                                                                                                        
  *White cell count ( × 10*^* *^ *l*^−*1*^)                                                            
   \<11                                       1556 (92.5)        70 (4.2)           56 (3.3)           \<0.001
   ⩾11                                        8 (29.6)           8 (29.6)           11 (40.7)           
                                                                                                        
  *Neutrophils ( × 10*^*9 *^*l*^−*1*^)                                                                 
   \<7.5                                      1498 (93.3)        65 (4.0)           42 (2.6)           \<0.001
   ⩾7.5                                       19 (38.0)          12 (24.0)          19 (38.0)           
                                                                                                        
  *Lymphocytes ( × 10*^*9*^* l*^−*1*^)                                                                 
   \<3                                        1458 (91.6)        75 (4.7)           59 (3.7)           0.633
   ⩾3                                         59 (93.7)          2 (3.2)            2 (3.2)             
                                                                                                        
  *CEA (ng ml*^−*1*^)                                                                                  
   ⩽5                                         1342 (93.6)        56 (3.9)           25 (2.4)           \<0.001
   \>5                                        184 (79.0)         20 (8.6)           29 (12.4)           
                                                                                                        
  *CA19-9 (ng ml*^−*1*^)                                                                               
   ⩽37                                        1299 (92.4)        57 (4.1)           50 (3.6)           0.006
   \>37                                       128 (84.8)         12 (7.9)           11 (7.3)            
                                                                                                        
  *Tumour stage*                                                                                       
   I                                          961 (96.4)         30 (3.0)           6 (0.6)            \<0.001
   II                                         177 (88.5)         9 (4.5)            14 (7.0)            
   III                                        219 (89.4)         13 (5.3)           13 (5.3)            
   IV                                         208 (77.6)         26 (9.7)           34 (12.7)           

Abbreviations: CEA=carcinoembryonic antigen; mGPS=modified Glasgow prognostic score.

*χ*^2^ test.

###### Univariate and multivariate analyses of overall survival

                               **Univariate analysis**   **Multivariate analysis**[a](#t3-fn2){ref-type="fn"}                                    
  ---------------------------- ------------------------- ------------------------------------------------------ -------------- --------- ------- --------------
  Sex                          0.187                     0.869                                                  0.706--1.070   ---       ---     ---
  Age                          \<0.001                   1.474                                                  1.217--1.784   0.010     1.319   1.068--1.629
  Body mass index              \<0.001                   0.503                                                  0.419--0.605   0.233     0.884   0.722--1.802
  Tumour location              0.088                     0.891                                                  0.781--1.017   0.276     0.929   0.813--1.061
  White cell count             0.161                     1.567                                                  0.837--2.933   ---       ---     ---
  Neutrophils                  \<0.001                   2.519                                                  1.668--3.805   0.153     0.681   0.402--1.153
  Lymphocytes                  0.212                     0.693                                                  0.391--1.231   ---       ---     ---
  CEA                          \<0.001                   3.121                                                  2.518--3.868   0.107     1.234   0.955--1.595
  CA19-9                       \<0.001                   4.059                                                  3.189--5.168   0.177     1.213   0.916--1.605
  Tumour stage (I/II/III/IV)   \<0.001                   2.974                                                  2.724--3.247   \<0.001   2.909   2.616--3.234
  mGPS (0, 1and 2)             \<0.001                   4.578                                                  3.324--6.306   0.007     1.845   1.184--2.875

Abbreviations: CEA=carcinoembryonic antigen; mGPS=modified Glasgow prognostic score.

Factors \<0.10 in univariate analysis were included in the multivariate analysis.
